Chung Claudia C Y, Leung Gordon K C, Mak Christopher C Y, Fung Jasmine L F, Lee Mianne, Pei Steven L C, Yu Mullin H C, Hui Vivian C C, Chan Joshua C K, Chau Jeffrey F T, Chan Marcus C Y, Tsang Mandy H Y, Wong Wilfred H S, Tung Joanna Y L, Lun Kin Shing, Ng Yiu Ki, Fung Cheuk Wing, Wong Mabel S C, Wong Rosanna M S, Lau Yu Lung, Chan Godfrey C F, Lee So Lun, Yeung Kit San, Chung Brian H Y
Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, China.
Lancet Reg Health West Pac. 2020 Jul 24;1:100001. doi: 10.1016/j.lanwpc.2020.100001. eCollection 2020 Aug.
Rapid whole-exome sequencing (rWES) offers the potential for early diagnosis-predicated precision medicine. Previous evidence focused predominantly on infants from the intensive care unit (ICU). This study sought to examine the diagnostic and clinical utility, and the economic impact on clinical management of rWES in patients beyond infancy and ICU setting.
rWES was performed on a prospective cohort of patients with suspected monogenic disorder referred from territory-wide paediatric ICUs and non-ICUs in Hong Kong urging for rapid genetic diagnosis. All eligible families were invited. We aimed to achieve a rapid turnaround time (TAT) of 14 days. Clinical utility and costs associated with clinical management were assessed in diagnosed cases. Actual quantitative changes in healthcare utilisation were compared with a counterfactual diagnostic trajectory and/or with matched historical control whenever possible.
rWES were offered to 102 families and 32/102 (31%) patients received a molecular diagnosis, with a median TAT of 11 days. Clinical management changed in 28 of 32 diagnosed patients (88%), including but not limited to modifications in treatment, avoidance of surgeries, and informing decisions on redirection of care. Cost analysis was performed in eight patients. rWES was estimated to reduce hospital length of stay by 566 days and decrease healthcare costs by HKD$8,044,250 (GBP£796,460) for these eight patients. The net cost-savings after inclusion of rWES costs were estimated to be HKD$5,325,187 (GBP£527,246).
This study replicates the diagnostic capacity and rapid TAT of rWES in predominantly Chinese patients, and demonstrates diagnosis-predicated precision medicine and net healthcare savings. Findings were corroborated by evidence from multinational cohorts, combined as part of a meta-analysis. rWES merits consideration as a first-tier diagnostic tool for patients with urgent needs in the clinical setting.
Health and Medical Research Fund, HKU Seed Fund for Basic Research, The Society for the Relief of Disabled Children, and Edward and Yolanda Wong Fund.
快速全外显子组测序(rWES)为基于早期诊断的精准医学提供了可能。既往证据主要集中在重症监护病房(ICU)的婴儿身上。本研究旨在探讨rWES在婴儿期以后及非ICU环境患者中的诊断和临床效用,以及对临床管理的经济影响。
对来自香港全港儿科ICU和非ICU的疑似单基因疾病患者的前瞻性队列进行rWES检测,以进行快速基因诊断。邀请了所有符合条件的家庭。我们的目标是实现14天的快速周转时间(TAT)。对确诊病例评估临床效用和与临床管理相关的成本。只要有可能,就将医疗资源利用的实际定量变化与反事实诊断轨迹和/或匹配的历史对照进行比较。
对102个家庭进行了rWES检测,32/102(31%)例患者获得了分子诊断,中位TAT为11天。32例确诊患者中有28例(88%)的临床管理发生了改变,包括但不限于治疗调整、避免手术以及为护理方向的决策提供信息。对8例患者进行了成本分析。估计rWES可使这8例患者的住院时间缩短566天,医疗费用降低8044250港元(796460英镑)。纳入rWES成本后的净成本节约估计为5325187港元(527246英镑)。
本研究在以华裔为主的患者中重复了rWES的诊断能力和快速TAT,并证明了基于诊断的精准医学和医疗净节约。来自多国队列的证据作为荟萃分析的一部分进行合并,证实了研究结果。rWES值得作为临床环境中有紧急需求患者的一线诊断工具加以考虑。
健康与医学研究基金、香港大学基础研究种子基金、残疾儿童救助协会以及黄爱德华和黄尤兰达基金。